This year, many people in the United States will see a lower price for insulin — but it’s not because the pharmaceutical companies chose to lower costs out of kindness.

Thanks to the organizing inside and outside of Congress, insulin was capped at $35 per month for Medicare recipients under the Inflation Reduction Act. Then, the American Rescue Plan Act contained a provision that removed Medicaid rebates for insulin for these drug manufacturers.

Together, these actions by Congress and President Biden forced Big Pharma to just cut the price of insulin altogether, after years of outrageous price-gouging.

While this is a relief for many patients across the country who rely on insulin, it doesn’t solve the high prices of other prescription drugs, health insurance premiums, co-pays, and other structural problems with our current health care system — which would be solved by a single-payer system like Medicare for All.

Let us be clear: the pharmaceutical companies never wanted to see these changes happen. In 2022, Big Pharma spent a record amount of money on lobbying to convince politicians to oppose allowing Medicare to negotiate drug prices. They were dealt a rare defeat with these measures to cap insulin prices, but their influence on our democracy remains outsized.

But together, we’re working to change that. Through our Patients Over Profits campaign, we’re building a movement of politicians committed to rejecting campaign contributions of $200 or more from the for-profit health care industry, including Big Pharma.

Sign up to join our Patients Over Profits special volunteer teams today to get involved and help us get Big Pharma and other for-profit health care interests out of our politics!

Sign Up »

With enough political will, we can overcome the opposition of the corporate health care industry and establish Medicare for All and guarantee health care — including insulin and other life-saving drugs — for ALL across the country.

In solidarity,

Nurses’ Campaign to Win Medicare for All